Your browser doesn't support javascript.
loading
EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.
Dickson, Rumona; Boland, Angela; Duarte, Rui; Kotas, Eleanor; Woolacott, Nerys; Hodgson, Robert; Riemsma, Rob; Grimm, Sabine; Ramaekers, Bram; Joore, Manuela; Büyükkaramikli, Nasuh; Kaltenthaler, Eva; Stevenson, Matt; Pandor, Abdullah; Edwards, Steve; Hoyle, Martin; Shepherd, Jonathan; Armoiry, Xavier; Brazzelli, Miriam.
Afiliação
  • Dickson R; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK. rdickson@liverpool.ac.uk.
  • Boland A; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
  • Duarte R; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
  • Kotas E; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
  • Woolacott N; Centre for Reviews and Dissemination, University of York, York, UK.
  • Hodgson R; Centre for Reviews and Dissemination, University of York, York, UK.
  • Riemsma R; Kleijnen Systematic Reviews, York, UK.
  • Grimm S; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Ramaekers B; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Joore M; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Büyükkaramikli N; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
  • Kaltenthaler E; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
  • Stevenson M; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
  • Pandor A; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
  • Edwards S; BMJ Technology Assessment Group, BMJ, London, UK.
  • Hoyle M; Peninsula Technology Assessment Group, University of Exeter Medical School, Exeter, UK.
  • Shepherd J; Southampton Health Technology Assessments Centre, University of Southampton, Southampton, UK.
  • Armoiry X; Warwick Evidence, University of Warwick, Coventry, UK.
  • Brazzelli M; Health Services Research Unit, University of Aberdeen, Aberdeen, UK.
Appl Health Econ Health Policy ; 16(4): 429-432, 2018 08.
Article em En | MEDLINE | ID: mdl-29808296
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Aprovação de Drogas / Antineoplásicos Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Appl Health Econ Health Policy Assunto da revista: SAUDE PUBLICA / SERVICOS DE SAUDE Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Aprovação de Drogas / Antineoplásicos Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Appl Health Econ Health Policy Assunto da revista: SAUDE PUBLICA / SERVICOS DE SAUDE Ano de publicação: 2018 Tipo de documento: Article